<DOC>
	<DOCNO>NCT00231439</DOCNO>
	<brief_summary>Inflammatory cytokine cerebrospinal fluid may contribute new muscle weakness , fatigue pain experience patient post-polio syndrome . Intravenousimmunoglobulin ( IvIg ) reduce inflammation . The purpose study investigate clinical effect IvIg post-polio syndrome .</brief_summary>
	<brief_title>Post-Poliosyndrome Treated With Intravenous Immunoglobulin ( IvIg )</brief_title>
	<detailed_description>Post-polio syndrome ( PPS ) characterise new muscle weakness , pain , fatigue several year attack acute polio . This lead increased disability , supportive therapy available . Patients PPS lose motor neuron expect survive neuron fail maintain neurogenic supply enlarge motor unit . New data report increase level inflammatory cytokine cerebrospinal fluid ( CSF ) . Immune modulate therapy like IvIg could option pilot study first investigate clinical effect IvIg PPS . In addition , level cytokine CSF serum treatment investigate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Postpoliomyelitis Syndrome</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Postpolio syndrome diagnose Dept Neurology , Haukeland University Hospital Walking ability Other autoimmune disorder Other ongoing autoimmune therapy Severe cardiopulmonary disease IgA deficiency Previous treatment IvIg Wheelchair dependence</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Months</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>Post-polio syndrome</keyword>
	<keyword>IvIg</keyword>
</DOC>